• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Agios Pharmaceuticals (AGIO) Is Down 7.7% After Halting Tebapivat While Advancing Mitapivat in Sickle Cell Disease – Has The Bull Case Changed?

    Simply Wall St·07/27/2026 23:30:33
    Listen to the news
    • Agios Pharmaceuticals recently reported topline Phase 2 results for tebapivat in sickle cell disease and, citing insufficient differentiation versus other pyruvate kinase activators, decided to halt further development in this indication despite observing hemoglobin and hemolysis improvements and a safety profile aligned with prior trials.
    • At the same time, the company is pursuing an alternative path in sickle cell disease through the FDA’s Priority Review of a supplemental New Drug Application for mitapivat, with a PDUFA decision date set for November 1, 2026.
    • Against this backdrop, we’ll examine how halting tebapivat while advancing mitapivat in sickle cell disease reshapes Agios’s investment narrative.

    Uncover the next big thing with 21 elite penny stocks that balance risk and reward.

    Agios Pharmaceuticals Investment Narrative Recap

    To own Agios today, you need to believe in the long term value of mitapivat across rare blood disorders and the company’s ability to translate that into meaningful revenue growth despite ongoing losses. The tebapivat setback in sickle cell disease narrows the pipeline but does not directly change the most important near term catalyst, which is the FDA’s Priority Review of mitapivat in sickle cell disease, or the key risk of high spending ahead of profitability.

    The most relevant recent announcement is the FDA’s Priority Review of the mitapivat sNDA in sickle cell disease, with a PDUFA decision date of November 1, 2026. This filing, based on the RISE UP data, now carries even more weight as tebapivat exits the indication, effectively concentrating sickle cell expectations onto a single asset at a time when Agios remains unprofitable and trading on a rich sales multiple.

    Yet, while the Priority Review offers a clear potential upside, investors should also be aware that...

    Read the full narrative on Agios Pharmaceuticals (it's free!)

    Agios Pharmaceuticals’ narrative projects $436.9 million revenue and $83.2 million earnings by 2029.

    Uncover how Agios Pharmaceuticals' forecasts yield a $40.88 fair value, a 11% upside to its current price.

    Exploring Other Perspectives

    AGIO 1-Year Stock Price Chart
    AGIO 1-Year Stock Price Chart

    Before this tebapivat news, the most cautious analysts were already assuming very fast revenue growth of about 72.5% a year to roughly US$339.0 million, which shows how differently you and other investors might frame the same mitapivat centered story and why it is worth weighing that more pessimistic view against the possibility that these forecasts could shift meaningfully from here.

    Explore 2 other fair value estimates on Agios Pharmaceuticals - why the stock might be worth over 7x more than the current price!

    The Verdict Is Yours

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Contemplating Other Strategies?

    These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.